Join us for two insightful presentations on using human biomimetic liver microphysiology system and quantitative systems toxicology models to study MASLD and DILI.

The first presentation, led by Lawrence Vernetti, PhD, focuses on the "3D Liver Microphysiological System for ADMET." This talk will discuss the use of a 3D multi-liver cell biomimetic of the human liver for predicting clinical intrinsic clearance and liver toxicity of drugs.

The second presentation, by Mark Miedel, PhD, is titled "Patient-Specific Microphysiology Systems: A New Precision Medicine Platform for Metabolic Dysfunction-Associated Steatotic Liver Disease." In this talk, Dr. Miedel will discuss the need for a precision medicine approach that considers individual variability in genetics, environment, and lifestyle offers promise to optimize therapeutic efficacy, minimize adverse effects, and improve the overall long-term outcome for MASLD patients. Our overall approach is to implement a precision medicine strategy using patient-specific microphysiology systems (MPS) using both genotyped primary cells and patient-specific induced pluripotent stem cells (iPSCs) as a solution to the challenge of addressing MASLD interpatient heterogeneity and to identify optimized patient cohorts for clinical trials. In this talk, we will discuss our liver acinus microphysiology systems (LAMPS) with both wild type and variant PNPLA3 hepatocytes and primary non-parenchymal cells to study disease-relevant metrics and examine response to drug treatment.

This presentation was originally aired on January 11, 2025.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2024 AASLD.

This activity does not offer CE Credit.